Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 912 | 134 | 765 |
| Samples | 452 | 84 | 362 |
| Peptides | 341 | 60 | 290 |
Function
SPATA18 · Spermatogenesis associated 18
This gene encodes a p53-inducible protein that is able to induce lysosome-like organelles within mitochondria that eliminate oxidized mitochondrial proteins, thereby contributing to mitochondrial quality control. Dysregulation of mitochondrial quality control is associated with cancer and degenerative diseases. The encoded protein mediates accumulation of the lysosome-like mitochondrial organelles through interaction with B cell lymphoma 2 interacting protein 3 and B cell lymphoma 2 interacting protein 3 like at the outer mitochondrial membrane, which allows translocation of lysosomal proteins to the mitochondrial matrix from the cytosol. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2016].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 326 amino-acid changes on canonical ENST00000295213 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in SPATA18 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in SPATA18 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Melanoma | 6/210 3% | 73/1899 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 17/612 3% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 40/1390 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Colorectal Carcinoma | 9/143 6% | 49/3239 2% |
| Gastric Carcinoma | 1/74 1% | 30/1809 2% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 9/810 1% |
| Other Solid Cancers | 2/94 2% | 18/1515 1% |
| Bladder Carcinoma | 4/58 7% | 8/956 1% |
| Hepatocellular Carcinoma | 0/46 0% | 23/2210 1% |
| Rhabdomyosarcoma | 1/33 3% | 1/171 1% |
| Esophageal Carcinoma | 0/23 0% | 7/769 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Neuroendocrine Tumour | 3/154 2% | 2/577 0% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Non-Cancerous | 3/104 3% | 3/830 0% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Ovarian Carcinoma | 1/109 1% | 5/998 0% |
| Prostate Carcinoma | 1/13 8% | 10/2105 0% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 12/2550 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 6/1592 0% |
Mutation Distribution
Where SPATA18 is mutated · all tissues, split by cell line vs tissue
How many mutations in SPATA18 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 912 mutations in SPATA18
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|